MPG.eBooks - Description: Palivizumab for infection prevention in Inuit infants

Cover Image

Read Now

Palivizumab for infection prevention in Inuit infants a review of the clinical effectiveness and cost-effectiveness

The purpose of this report is to determine the clinical effectiveness and cost effectiveness of universal versus high-risk palivizumab prophylaxis, and seasonal versus year-round palivizumab in Inuit children up to 4 years of age

Bibliographic Details
Main Authors:	La Fleur, Philip, Argáez, Charlene (Author)
Corporate Author:	Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health December 17, 2019, 2019
Edition:	Version 1.0
Series:	CADTH rapid response report: summary with critical appraisal
Subjects:	Inuits Comparative Effectiveness Research Canada Infant Respiratory Syncytial Virus Infections / Prevention & Control Palivizumab / Therapeutic Use Cost-benefit Analysis Child, Preschool Treatment Outcome
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK562830
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The purpose of this report is to determine the clinical effectiveness and cost effectiveness of universal versus high-risk palivizumab prophylaxis, and seasonal versus year-round palivizumab in Inuit children up to 4 years of age
Physical Description:	1 PDF file (8 pages) illustrations